MARKET

EYEG

EYEG

EyeGate Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.480
-0.240
-5.08%
Opening 13:49 11/19 EST
OPEN
4.610
PREV CLOSE
4.720
HIGH
4.649
LOW
4.450
VOLUME
18.39K
TURNOVER
--
52 WEEK HIGH
8.85
52 WEEK LOW
2.250
MARKET CAP
16.29M
P/E (TTM)
-1.8270
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of EYEG and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

EYEG News

  • EYEG: OBG-PRK Pivotal Data Upcoming, 2020 Launch? OBG-PE Pre-Pivotal Study Moving Quick, Pivotal in 2020?
  • Zacks Small Cap Research.5d ago
  • Eyegate Pharmaceuticals reports Q3 results
  • seekingalpha.11/07 17:26
  • EyeGate Pharma Reports Third Quarter 2019 Financial Results and Provides Business Update
  • ACCESSWIRE.11/07 11:55
  • EyeGate Pharma up 22% ahead of key data readout
  • Seeking Alpha - Article.10/31 19:25

More

Industry

Pharmaceuticals
+0.34%
Pharmaceuticals & Medical Research
+0.71%

Hot Stocks

Name
Price
%Change

About EYEG

Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.
More

Webull offers Eyegate Pharmaceuticals Inc (EYEG) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.